AstraZeneca Statistics

Total Valuation

AstraZeneca has a market cap or net worth of SEK 2.20 trillion. The enterprise value is 2.48 trillion.

Market Cap	2.20T
Enterprise Value	2.48T

Important Dates

The next estimated earnings date is Thursday, February 6, 2025.

Earnings Date	Feb 6, 2025
Ex-Dividend Date	Aug 8, 2024

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+0.22%
Shares Change (QoQ)	+0.13%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	1.54B

Valuation Ratios

The trailing PE ratio is 33.44.

PE Ratio	33.44
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 12.87, with an EV/FCF ratio of 25.48.

EV / Earnings	37.64
EV / Sales	4.68
EV / EBITDA	12.87
EV / EBIT	17.57
EV / FCF	25.48

Financial Position

The company has a current ratio of 0.93, with a Debt / Equity ratio of 0.77.

Current Ratio	0.93
Quick Ratio	0.71
Debt / Equity	0.77
Debt / EBITDA	1.69
Debt / FCF	3.30
Interest Coverage	10.12

Financial Efficiency

Return on equity (ROE) is 16.66% and return on invested capital (ROIC) is 12.28%.

Return on Equity (ROE)	16.66%
Return on Assets (ROA)	8.50%
Return on Capital (ROIC)	12.28%
Revenue Per Employee	5.78M
Profits Per Employee	732,752
Employee Count	89,900
Asset Turnover	0.51
Inventory Turnover	1.63

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +6.39% in the last 52 weeks. The beta is 0.17, so AstraZeneca's price volatility has been lower than the market average.

Beta (5Y)	0.17
52-Week Price Change	+6.39%
50-Day Moving Average	1,492.34
200-Day Moving Average	1,586.56
Relative Strength Index (RSI)	41.34
Average Volume (20 Days)	299,463

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, AstraZeneca had revenue of SEK 519.35 billion and earned 65.87 billion in profits. Earnings per share was 42.09.

Revenue	519.35B
Gross Profit	429.01B
Operating Income	138.68B
Pretax Income	80.35B
Net Income	65.87B
EBITDA	186.53B
EBIT	138.68B
Earnings Per Share (EPS)	42.09

Full Income Statement

Balance Sheet

The company has 50.00 billion in cash and 320.63 billion in debt, giving a net cash position of -270.63 billion.

Cash & Cash Equivalents	50.00B
Total Debt	320.63B
Net Cash	-270.63B
Net Cash Per Share	n/a
Equity (Book Value)	413.86B
Book Value Per Share	266.44
Working Capital	-17.96B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 114.95 billion and capital expenditures -17.66 billion, giving a free cash flow of 97.30 billion.

Operating Cash Flow	114.95B
Capital Expenditures	-17.66B
Free Cash Flow	97.30B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 82.61%, with operating and profit margins of 26.70% and 12.68%.

Gross Margin	82.61%
Operating Margin	26.70%
Pretax Margin	15.47%
Profit Margin	12.68%
EBITDA Margin	35.92%
EBIT Margin	26.70%
FCF Margin	18.73%

Dividends & Yields

This stock pays an annual dividend of 31.44, which amounts to a dividend yield of 2.19%.

Dividend Per Share	31.44
Dividend Yield	2.19%
Dividend Growth (YoY)	3.66%
Years of Dividend Growth	2
Payout Ratio	71.25%
Buyback Yield	-0.22%
Shareholder Yield	1.97%
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

AstraZeneca has an Altman Z-Score of 3.02.

Altman Z-Score	3.02
Piotroski F-Score	n/a